Trump DL - Search Results

1

Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.

Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Trump DL, et al. Cancer. 2006 May 15;106(10):2136-42. doi: 10.1002/cncr.21890. Cancer. 2006. PMID: 16598750 Free article. Clinical Trial.

2

Vitamin D-related therapies in prostate cancer.

Johnson CS, Hershberger PA, Trump DL. Johnson CS, et al. Among authors: trump dl. Cancer Metastasis Rev. 2002;21(2):147-58. doi: 10.1023/a:1020836226594. Cancer Metastasis Rev. 2002. PMID: 12465754 Review.

3

Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Trump DL, et al. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26. doi: 10.1016/j.jsbmb.2004.03.068. J Steroid Biochem Mol Biol. 2004. PMID: 15225831 Review.

4

Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.

Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Muindi JR, et al. Among authors: trump dl. Cancer Chemother Pharmacol. 2005 Nov;56(5):492-6. doi: 10.1007/s00280-005-1015-2. Epub 2005 May 26. Cancer Chemother Pharmacol. 2005. PMID: 15918041 Clinical Trial.

5

Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients.

Muindi JR, Peng Y, Wilson JW, Johnson CS, Branch RA, Trump DL. Muindi JR, et al. Among authors: trump dl. Cancer Chemother Pharmacol. 2007 Jan;59(1):97-104. doi: 10.1007/s00280-006-0247-0. Epub 2006 May 6. Cancer Chemother Pharmacol. 2007. PMID: 16680461 Clinical Trial.

6

The antitumor efficacy of calcitriol: preclinical studies.

Johnson CS, Muindi JR, Hershberger PA, Trump DL. Johnson CS, et al. Among authors: trump dl. Anticancer Res. 2006 Jul-Aug;26(4A):2543-9. Anticancer Res. 2006. PMID: 16886662 Free article. Review.

7

Vitamin D compounds: clinical development as cancer therapy and prevention agents.

Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Trump DL, et al. Anticancer Res. 2006 Jul-Aug;26(4A):2551-6. Anticancer Res. 2006. PMID: 16886663 Free article.

8

Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells.

Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Ma Y, et al. Among authors: trump dl. Cancer Res. 2006 Aug 15;66(16):8131-8. doi: 10.1158/0008-5472.CAN-06-1333. Cancer Res. 2006. PMID: 16912191

9

Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells.

Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Chung I, et al. Among authors: trump dl. Cancer Res. 2006 Sep 1;66(17):8565-73. doi: 10.1158/0008-5472.CAN-06-0905. Cancer Res. 2006. PMID: 16951169

10

A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.

Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS. Fakih MG, et al. Among authors: trump dl. Clin Cancer Res. 2007 Feb 15;13(4):1216-23. doi: 10.1158/1078-0432.CCR-06-1165. Clin Cancer Res. 2007. PMID: 17317832 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters